Abstract
The character of lipid spectrum changes in rats with experimental heart failure of non-ischemic genesis depended on its severity. In mild heart failure there was found an increase in the low-density lipoprotein levels, whereas in the severe one-a decrease of total cholesterol levels at the expense of low-density lipoproteins. The ACE inhibitors produced no significant changes in the lipid spectrum. The effect of β-adrenoblockers was determined by their selectivity for β1-adrenoreceptors. The most selective drugs were distinguished by the metabolically neutral activity. On the contrary, nonselective β-adrenoblockers increased the degree of plasma atherogeneity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mareev, V.Yu., Ageev, F.T., Arutyunov, A.G., Koroteev, A.V., and Revishvili, F.V., National Recommendations WNOK and OSSN about the Diagnostics and Treatment of CHF) (the Third Revision), Serdech. Nedostat., 2010, vol. 11, no. 1, pp. 3–62.
Arutyunov, G.P. and Ageev, F.T., The Hypolipidemic Therapy in Patients with CHF. Whom? When? By What?, Serdech. Nedostat., 2003, vol. 4, no.4, pp. 206–212.
Velavan, P., Huan Loh, P., Clark, A., and Cleland, J.G., The Cholesterol Paradox in Heart Failure, Congest. Heart Fail., 2007, vol. 13, no. 6, pp. 336–341.
Horwich, T., Low-Density Lipoprotein in the Setting of Congestive Heart Failure: Is Lower Really Better?, Curr. Atheroscler. Rep., 2009, vol. 11, no. 5, pp. 343–349.
Rauchhaus, M., Clark, A.L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A.J.S., and Anker, S.D., The Relationship between Cholesterol and Survival in Patients with Chronic Heart Failure, J. Am. Coll. Cardiol., 2003, vol. 42, pp. 1933–1943.
Charach, G., George, J., Roth, A., Rogowski, O., Wexler, D., Sheps, D., Grosskopf, I., Weintraub, M., Keren, G., and Rubinstein, A., Baseline Low-Density Lipoprotein Cholesterol Levels and Outcome in Patients with Heart Failure, Am. J. Cardiol., 2010, vol. 105, no. 1, pp. 100–104.
Martyov, A.I., Ostroumova, O.D., Mamaev, V.I., Rybkina, T.E., Kuznetsov, V.I., Tikhonova, L. Ya., and Smirnova, M.V., Effect of Antihypertensive Preparations on the Lipid Metabolism. Part I. Diuretics, β-Blockers, Calcium Antagonists, Klin. Med., 2001, vol. 79, no. 8, pp. 8–12.
Pyatnitskii, N.N. and Blinkov, Yu.A., About the Problem of Modeling of the Right Heart Failure, Kardiologiya, 1970, no. 1, pp. 143–144.
Rumyantseva, T.A., Fateev, M.M., Fedorov, V. N., Salnikov, E.V., and Sidorov, A.V., Morphological Proofs of the Presence for the Chronic Heart Failure Induced in Rats by the Method of Fractional Dosed Oleothorax, Vest. Nizhegor. Unta, 2009, no. 5, pp. 123–127.
Guskova, T.A., Evaluation of Safety of the Medicinal Drugs at the Stage of the Preclinical Study, Khimiko-Farmatsevt. Zh., 1990, no. 7, pp. 10–15.
Kamyshnikov, V.S., Kliniko-biokhimicheskya laboratornaya diagnostika: spravochnik: v 2 tomakh (The Clinical-Biochemical Laboratory Diagnostics: Reference Book: in 2 Volumes), vol. 2, the 2nd Edit., Minsk, 2003.
Clark, A.L. and Coats, A.J.S., Changes in Lower Limb Skeletal Muscle and Mechanisms of Fatigue in Chronic Heart Failure, Basic App. Myol., 1995, vol. 5, pp. 349–358.
Beer, M., Seyfarth, T., Sandstede, J., Landschütz, W., Lipke, C., Kustler, H., von Kienlin, M., Harre, K., Hahn, D., and Neubauer, S., Absolute Concentrations of High-Energy Phosphate Metabolites in Normal, Hypertrophied, and Failing Human Myocardium Measured Noninvasively with (31)P-SLOOP Magnetic Resonance Spectroscopy, J. Am. Coll. Cardiol., 2002, vol. 40, pp. 1267–1274.
Stanley, W.C., Recchia, F.A., and Lopaschuk, G.D., Myocardial Substrate Metabolism in the Normal and Failing Heart, Physiol. Rev., 2005, vol. 85, pp. 1093–1129.
Bobyreva, L.E., Samarchenko, L.A., Bobyrev, V.N., and Voskresenskii, O.N., The State of Free-Radical Lipid Oxygenation in Patients with Cerebral Atherosclerosis Depending on the Disease Stage, Korsakov Zh. Nevropatol. Psikhiat., 1987, vol. LXXXVII, no. 9, pp. 1309–1312.
Volchegorskii, I.A., Shaposhnik, I.I., Alexeev, E.N., and Kharchenkova, N.V., The Indices of System “Lipid Peroxidation-Antioxidant Protection” as Markers of Chronic Heart Failure in Cardiomyopathies, Klin. Med., 2003, vol. 81, no. 8, pp. 26–28.
Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv (Handbook of Experimental (Preclinical) Investigation of Novel Pharmacologic Substances), Khabriev, R.U., Ed., 2nd Edit., Revis, and Updat., Moscow, 2005.
Rauchhause, M., Coats, A.J.S., and Anker, S.D., Endotoxin-Lipoprotein Hypothesis, Lancet, 2000, vol. 356, pp. 930–933.
Anker, S.D., Chua, T.P., Ponikowski, P., Harrington, D., Swan, J.W., Kox, W.J., Poole-Wilson, P.A., and Coats, A.J., Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia, Circulation, 1997, vol. 96, no. 2, pp. 526–534.
Preobrazhenskii, D.V., Sidorenko, B.A., Pataraya, S.A., and Nekrasova, N.I., Nebivolol-β-adrenoblocker of the Third Generation in Treatment of Cardiovascular Diseases, Ross. Med. Zh., 2008, vol. 16, no. 5, pp. 277–285.
Rabkin, S.W., Mechanisms of Action of Adrenergic Receptor Blockers on Lipids during Antihypertensive Treatment, J. Clin. Pharmacol., 1993, vol. 33, pp. 286–291.
Ivleva, A.Ya., Differences of Pharmacologic Properties of Beta-Adrenoblockers and Their Clinic Significance, Consilium medicum, 2003, vol. 5, no. 11, pp. 641–648.
Kukharchuk, V.V., Dislipdemias and Cardiovascular Diseases (Part 1), Bolezni Serdtsa i Sosudov, 2009, no. 1, pp. 20–24.
Akhmedova, O.O., Gavrilov, Yu.V., Petrii, V.V., Buvaltsev, V.I., and Makolkin, V.I., The Antihypertensive Effectiveness of Cardioselective β-Adrenoblockers-Nebivolol and Metoprolol in Monotherapy in Patients with Mild and Moderate Arterial Hypertension in Combination with Type II Diabetes Mellitus, Ross. Cardiol. Zh., 2003, no. 2, pp. 44–48.
Teplyakov, A.T., Kusnetsova, A.V., Stepacheva, T.A., Dyakova, M.L., Shilov, S.N., and Bolotskaya, L.A., The Anti-ischemic and Metabolic Effects of Nebivolol and Metoprolol CR/XL in Patients with Post-infarct Heart Dysfunction, Klin. Med., 2005, vol. 83, no. 4, pp. 56–59.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.V. Sidorov, M.M. Fateev, 2013, published in Zhurnal Evolyutsionnoi Biokhimii i Fiziologii, 2013, Vol. 49, No. 4, pp. 272–277.
Rights and permissions
About this article
Cite this article
Sidorov, A.V., Fateev, M.M. Changes in lipid spectrum in rats with chronic heart failure of different severity on the background of angiotensin-converting enzyme inhibitors and beta-adrenoblockers. J Evol Biochem Phys 49, 408–414 (2013). https://doi.org/10.1134/S002209301304004X
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S002209301304004X